Welcome to our dedicated page for Heron Therapeutics news (Ticker: HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics stock.
Heron Therapeutics, Inc. (Nasdaq: HRTX) is a commercial-stage biotechnology company whose news flow is closely tied to its acute care and oncology supportive care portfolio. The company regularly issues updates on its marketed products ZYNRELEF, APONVIE, CINVANTI, and SUSTOL, as well as financial and corporate developments that affect HRTX stock.
On this page, readers can follow HRTX news related to quarterly and annual financial results, net revenue trends by product, and guidance updates disclosed in earnings press releases. Heron’s announcements often break out performance for its Acute Care franchise, which includes ZYNRELEF for postoperative pain and APONVIE for prevention of postoperative nausea and vomiting in adults, and its Oncology franchise, which includes CINVANTI and SUSTOL for prevention of chemotherapy-induced nausea and vomiting.
Company news also covers regulatory and clinical milestones for Heron’s products. Examples from past releases include FDA approvals and label expansions for ZYNRELEF in various soft tissue and orthopedic surgical procedures, and recognition of APONVIE in consensus guidelines for the management of postoperative nausea and vomiting. These items help investors and clinicians track how product indications and clinical positioning evolve over time.
In addition, Heron reports capital markets and governance events through press releases and corresponding SEC filings. Recent topics have included comprehensive capital restructuring, new credit facilities and convertible note transactions, adoption of a Tax Benefit Preservation Plan to protect net operating loss carryforwards, and Board-level changes such as cooperation agreements with investors and director appointments. For users monitoring HRTX, this news feed offers a consolidated view of operational, financial, regulatory, and governance developments that the company has publicly disclosed.
Heron Therapeutics (HRTX) announced a conference call for May 9, 2022, at 4:30 p.m. ET to discuss its first quarter financial results and recent business highlights. The call can be accessed via telephone or web, and an archive will be available for 60 days. The company is focused on developing best-in-class treatments aimed at fulfilling unmet patient needs in acute care and oncology. Caution is advised regarding forward-looking statements due to inherent risks and uncertainties.
Heron Therapeutics, Inc. (Nasdaq: HRTX) will participate in a fireside chat at the 21st Annual Virtual Needham Healthcare Conference on April 11, 2022, at 8:00 am PT. The event aims to discuss the company's innovative approaches to addressing unmet patient needs in acute care and oncology through best-in-class treatments. A live webcast will be available on the company's website in the Investor Resources section. For more information about Heron and its products, please visit www.herontx.com.
Heron Therapeutics announced that the Centers for Medicare & Medicaid Services (CMS) approved transitional pass-through status for ZYNRELEF, effective April 1, 2022. This status allows ZYNRELEF to be reimbursed separately in Hospital Outpatient Departments (HOPD) and Ambulatory Surgical Centers (ASC) for three years, enhancing access for patients needing postoperative pain relief. With 72% of ZYNRELEF procedures occurring in outpatient settings, this approval positions Heron advantageously against competitors. ZYNRELEF is the first dual-acting local anesthetic approved for up to 72 hours of pain relief following various surgical procedures.
Heron Therapeutics, Inc. announced that Health Canada has approved ZYNRELEF, an extended-release local anesthetic, for postoperative analgesia following specific surgeries. This product is notable as it's the only extended-release bupivacaine approved in Canada, combining bupivacaine and meloxicam to enhance pain relief while reducing opioid use. The company intends to expand ZYNRELEF's indications and reduce costs through manufacturing supplements. This approval is seen as a significant step in addressing the opioid crisis.
Heron Therapeutics, Inc. (Nasdaq: HRTX) will participate in a fireside chat at the 42nd Annual Cowen Healthcare Conference on March 7, 2022, at 11:10 am PT. The live webcast will be accessible on their website in the Investor Resources section. As a commercial-stage biotechnology company, Heron focuses on developing innovative treatments for unmet patient needs in acute care and oncology. Their advanced science and patented technologies have led to a unique portfolio aimed at enhancing standards of care. More information is available at www.herontx.com.
Heron Therapeutics, Inc. (HRTX) announced its financial results for Q4 and FY 2021, reporting net product sales of $20.7 million and $86.3 million, respectively. The net loss decreased to $54.6 million for Q4 2021, improving from $62.3 million in Q4 2020. Key highlights include the successful launch of ZYNRELEF, now covering 7 million procedures annually, with net sales reaching $2.9 million. Anticipated guidance for Q1 2022 oncology care franchise sales is $20 million to $22 million. The company aims to moderate cash usage as sales grow.
Heron Therapeutics (HRTX) announced a conference call on February 28, 2022, at 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results along with recent business developments. The call can be accessed via phone or webcast on Heron's website. The company aims to enhance patient care through innovative treatments and is committed to addressing unmet medical needs in acute care and oncology. Further details will be available during the call and afterwards on Heron's website.
Heron Therapeutics (HRTX) announced FDA approval for a supplemental New Drug Application for ZYNRELEF, expanding its use in adults for postoperative pain management after various surgeries. This approval enhances ZYNRELEF's indication for up to 72 hours of pain relief in approximately 7 million procedures annually, positioning it as a leading alternative to opioids. The clinical data show ZYNRELEF's superior efficacy over the standard bupivacaine solution. Additionally, reimbursement for the drug now covers up to 120 million lives, broadening its market potential.
Heron Therapeutics (Nasdaq: HRTX) announced the submission of a New Drug Application (NDA) for HTX-019, an injectable emulsion of aprepitant aimed at preventing postoperative nausea and vomiting (PONV) in adults. The NDA includes data supporting the bioequivalence of HTX-019 32 mg IV injection to 40 mg oral aprepitant. This formulation offers faster and more reliable drug exposure, addressing the significant unmet need for effective PONV prevention. Aprepitant is the only NK1 receptor antagonist approved for this indication, with potential benefits for millions of surgical patients annually.
Heron Therapeutics (Nasdaq: HRTX) announced its participation in upcoming investor conferences, focusing on enhancing patient care through innovative treatments. At the Jefferies London Healthcare Conference on November 18-19, 2021, a fireside chat will be available on-demand. Additionally, during the 4th Annual Evercore ISI HealthCONx Conference from November 30 - December 2, 2021, a live fireside chat is scheduled for December 1 at 2:40 PM ET. Webcasts of these events can be accessed via the Company's website.